{"pageContent": "Aim: To assess the validity of PSA doubling time (PSADT) as a predictor of prostate sextant biopsy outcome in patients with PSA levels in the 4-10 ng/mL range.", "metaData": {"source": "Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria\nhttps://pubmed.ncbi.nlm.nih.gov/22298223/"}}